SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Edén Engström Britt))
 

Search: (WFRF:(Edén Engström Britt)) > (2015-2019) > Long-term safety of...

  • Nilsson, Anna G.Department of Endocrinology, Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (author)

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency : a phase 3b, open-label, extension study

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • Bioscientifica,2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-110180
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-110180URI
  • https://doi.org/10.1530/eje-17-0067DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agency:ViroPharma (now Shire International GmbH)
  • Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydrocortisone (DR-HC) tablet as oral glucocorticoid replacement therapy in patients with primary adrenal insufficiency (AI).Design: Prospective, open-label, multicenter, 5-year extension study of DR-HC conducted at five university clinics in Sweden.Methods: Seventy-one adult patients diagnosed with primary AI who were receiving stable glucocorticoid replacement therapy were recruited. Safety and tolerability outcomes included adverse events (AEs), intercurrent illness episodes, laboratory parameters and vital signs. Quality of life (QoL) was evaluated using generic questionnaires.Results: Total DR-HC exposure was 328 patient-treatment years. Seventy patients reported 1060 AEs (323 per 100 patient-years); 85% were considered unrelated to DR-HC by the investigator. The most common AEs were nasopharyngitis (70%), fatigue (52%) and gastroenteritis (48%). Of 65 serious AEs reported by 32 patients (20 per 100 patient-years), four were considered to be possibly related to DR-HC: acute AI (n = 2), gastritis (n = 1) and syncope (n = 1). Two deaths were reported (fall from height and subarachnoid hemorrhage), both considered to be unrelated to DR-HC. From baseline to 5 years, intercurrent illness episodes remained relatively stable (mean 2.6-5.4 episodes per patient per year), fasting plasma glucose (0.7 mmol/L; P < 0.0001) and HDL cholesterol (0.2 mmol/L; P < 0.0001) increased and patient-/investigator-assessed tolerability improved. QoL total scores were unchanged but worsening physical functioning was recorded (P = 0.008).Conclusions: In the first prospective study evaluating the long-term safety of glucocorticoid replacement therapy in patients with primary AI, DR-HC was well tolerated with no safety concerns observed during 5-year treatment.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bergthorsdottir, RagnhildurDepartment of Endocrinology, Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (author)
  • Burman, PiaDepartment of Endocrinology, Skåne University Hospital Malmö, University of Lund, Lund, Sweden (author)
  • Dahlqvist, PerDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden (author)
  • Ekman, BertilDepartments of Endocrinology and Medical and Health Sciences, Linköping University, Linköping, Sweden (author)
  • Engström, Britt EdénDepartment of Medical Sciences, Endocrinology and Metabolism, University Hospital, Uppsala, Sweden (author)
  • Ragnarsson, OskarDepartment of Endocrinology, Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (author)
  • Skrtic, StankoDepartment of Endocrinology, Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; AstraZeneca R&D, Mölndal, Sweden (author)
  • Wahlberg, Jeanette,1969-Departments of Endocrinology and Medical and Health Sciences, Linköping University, Linköping, Sweden(Swepub:oru)jewg (author)
  • Achenbach, HeinrichShire International GmbHZug, Switzerland (author)
  • Uddin, SharifShireLexington, Massachusetts, USA (author)
  • Marelli, ClaudioShire International GmbHZug, Switzerland (author)
  • Johannsson, GudmundurDepartment of Endocrinology, Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (author)
  • Department of Endocrinology, Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenDepartment of Endocrinology, Skåne University Hospital Malmö, University of Lund, Lund, Sweden (creator_code:org_t)

Related titles

  • In:European Journal of Endocrinology: Bioscientifica176:6, s. 715-7250804-46431479-683X

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view